Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan Health supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan Health customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators.

Company profile
Ticker
MGLN
Exchange
Website
CEO
Kenneth J. Fasola
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CHARTER MEDICAL CORP, MAGELLAN HEALTH SERVICES INC
SEC CIK
Corporate docs
Subsidiaries
Magellan Pharmacy Services, Inc. • AdvoCare of Tennessee, Inc. • Magellan Method, LLC • Magellan Administrative Services, LLC • Magellan Behavioral Health of New Jersey, LLC • Magellan Behavioral of Michigan, Inc. • Magellan Health Services of California, Inc. • Magellan Rx Management IPA, Inc. • Magellan Rx Pharmacy, LLC • ONCORE Healthcare, LLC ...
IRS number
581076937
MGLN stock data
Press releases
Magellan Healthcare Provides Resources in Support of BIPOC Mental Health Awareness Month in July
24 Jun 22
Magellan Healthcare Provides Resources to Address Growing Needs and Bring Awareness During Mental Health Month
28 Apr 22
Magellan Healthcare Announces New Collaboration with Concert Genetics to Improve Genetic Testing
25 Apr 22
Calendar
5 Nov 21
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.04B | 1.04B | 1.04B | 1.04B | 1.04B | 1.04B |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 319.08K | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | 2.84M | n/a | n/a |
Cash remaining | n/a | n/a | n/a | 1.04B | n/a | n/a |
Runway (months of cash) | n/a | n/a | n/a | 3245.6 | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Jan 22 | Abbott Swati Bargotra | Ordinary Common Stock, $0.01 par value | Sale back to company | Dispose D | No | No | 0 | 6,847 | 0 | 0 |
4 Jan 22 | David Bourdon | Ordinary Common Stock, $0.01 par value | Sale back to company | Dispose D | No | No | 0 | 1,330 | 0 | 0 |
4 Jan 22 | David Bourdon | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 4,362 | 0 | 0 |
4 Jan 22 | David Bourdon | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 16,963 | 0 | 0 |
4 Jan 22 | David Bourdon | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 4,383 | 0 | 0 |
4 Jan 22 | Kenneth J Fasola | Ordinary Common Stock, $0.01 par value | Sale back to company | Dispose D | No | No | 0 | 17,141 | 0 | 0 |
4 Jan 22 | Kenneth J Fasola | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 27,743 | 0 | 0 |
4 Jan 22 | Kenneth J Fasola | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 18,411 | 0 | 0 |
4 Jan 22 | Kenneth J Fasola | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 43,080 | 0 | 0 |
4 Jan 22 | Kenneth J Fasola | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 22,196 | 0 | 0 |
Institutional ownership, Q1 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 172 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 106K |
Total shares | 1.14K |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ancora Advisors | 1K | $93K |
Allspring Global Investments | 142 | $13K |
Starboard Value | 0 | $0 |
Financial report summary
?Competition
CignaManagement Discussion
- Net revenue, cost of care, cost of goods sold, and direct service costs and other operating expense variances are addressed within the segment results that follow.
- Depreciation and amortization expense decreased by 10.9 percent or $12.0 million from 2019 to 2020, primarily due to asset maturities and office impairments, partially offset by normal asset additions in the current year.
- Interest expense decreased by $5.0 million from 2019 to 2020 primarily due to lower interest rates and lower debt balances.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
entry, fourth
Removed:
exit
Financial reports
Current reports
8-K
Termination of a Material Definitive Agreement
4 Jan 22
8-K
Centene and Magellan Satisfy All Regulatory Approvals
30 Dec 21
8-K
Magellan Health Reports Third Quarter 2021 Financial Results
5 Nov 21
8-K
Magellan Health Reports Second Quarter 2021 Financial Results
5 Aug 21
8-K
Magellan Health Reports First Quarter 2021 Financial Results
30 Apr 21
8-K
Submission of Matters to a Vote of Security Holders
31 Mar 21
8-K
Other Events
19 Mar 21
8-K
Magellan Health Reports 2020 Financial Results
26 Feb 21
8-K/A
Financial Statements and Exhibits
6 Jan 21
8-K
Ken Fasola’s Employee Announcement Email
4 Jan 21
Registration and prospectus
15-12B
Securities registration termination
14 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Jan 22
25-NSE
Exchange delisting
4 Jan 22
S-8
Registration of securities for employees
11 Jun 18
424B2
Prospectus for primary offering
17 Sep 17
424B2
Prospectus for primary offering
14 Sep 17
Proxies
DEFA14A
Additional proxy soliciting materials
19 Mar 21
DEFM14A
Proxy related to merger
19 Feb 21
PREM14A
Preliminary proxy related to merger
8 Feb 21
DEFA14A
Additional proxy soliciting materials
4 Jan 21
DFAN14A
Additional proxy materials by non-management
4 Jan 21
DEFA14A
Additional proxy soliciting materials
4 Jan 21
DEFA14A
Additional proxy soliciting materials
4 Jan 21
DEFA14A
Additional proxy soliciting materials
4 Jan 21
DEFA14A
Additional proxy soliciting materials
2 Jun 20
DEF 14A
Definitive proxy
29 Apr 20
Other
UPLOAD
Letter from SEC
29 May 17
CORRESP
Correspondence with SEC
18 May 17
UPLOAD
Letter from SEC
9 May 17
UPLOAD
Letter from SEC
31 Aug 16
CORRESP
Correspondence with SEC
28 Aug 16
CT ORDER
Confidential treatment order
22 Aug 16
UPLOAD
Letter from SEC
1 Aug 16
UPLOAD
Letter from SEC
9 Sep 15
CORRESP
Correspondence with SEC
10 Aug 15
UPLOAD
Letter from SEC
30 Jul 15
Ownership
SC 13G
MAGELLAN HEALTH / UBS OCONNOR ownership change
14 Feb 22
SC 13G/A
MAGELLAN HEALTH / VANGUARD ownership change
10 Feb 22
SC 13G/A
MAGELLAN HEALTH / DIMENSIONAL FUND ADVISORS ownership change
7 Feb 22
SC 13G/A
MAGELLAN HEALTH / VICTORY CAPITAL MANAGEMENT ownership change
2 Feb 22
SC 13G/A
MAGELLAN HEALTH / BlackRock ownership change
26 Jan 22
SC 13G
MAGELLAN HEALTH / BlackRock ownership change
25 Jan 22
SC 13D/A
MAGELLAN HEALTH / Starboard Value ownership change
6 Jan 22
4
MAGELLAN HEALTH / Peter A Feld ownership change
4 Jan 22
4
MAGELLAN HEALTH / JEFFREY N WEST ownership change
4 Jan 22
4
MAGELLAN HEALTH / STEVEN J SHULMAN ownership change
4 Jan 22
Patents
Utility
Method and Apparatus for Controlled Relative Motion of Surgical Instruments and Components
14 Oct 21
Provided herein are devices, systems, and methods for providing controlled delivery of a therapeutic substance during a surgical procedure, the devices and systems including a base, a frame having a proximal end and a distal end attached to the base, an injection subassembly including a plunger shaft, a relative motion subassembly including a lever plate, and a fastener configured to connect the plunger shaft of the injection subassembly and the lever plate of the relative motion subassembly.
Utility
Method and apparatus for controlled relative motion of surgical instruments and components
27 Jul 21
Provided herein are devices, systems, and methods for providing controlled delivery of a therapeutic substance during a surgical procedure, the devices and systems including a base, a frame having a proximal end and a distal end attached to the base, an injection subassembly including a plunger shaft, a relative motion subassembly including a lever plate, and a fastener configured to connect the plunger shaft of the injection subassembly and the lever plate of the relative motion subassembly.
Transcripts
2020 Q3
Earnings call transcript
31 Oct 20
2020 Q2
Earnings call transcript
29 Jul 20
2020 Q1
Earnings call transcript
11 May 20
2019 Q4
Earnings call transcript
28 Feb 20
2019 Q3
Earnings call transcript
1 Nov 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
5 May 19
2018 Q4
Earnings call transcript
28 Feb 19
2018 Q3
Earnings call transcript
10 Nov 18
2018 Q2
Earnings call transcript
27 Jul 18